{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:11:04Z","timestamp":1759479064956,"version":"build-2065373602"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04813-5","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T07:34:50Z","timestamp":1759476890000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comment on: Dose adjustment strategy for high dose methotrexate-induced toxicities in pediatric acute lymphoblastic leukemia: based on population PK analysis and exposure toxicity relationship"],"prefix":"10.1007","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5364-3275","authenticated-orcid":false,"given":"Ian J.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"4813_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-025-04750-3","volume":"95","author":"A Cao","year":"2025","unstructured":"Cao A, Guan Y, Wang J (2025) Dose adjustment strategy for high-dose methotrexate \u2013 induced toxicities in pediatric acute lymphoblastic leukemia:based on population PK analysis and exposure -toxicity relationship. Cancer Chemother Pharmocol 95:33. https:\/\/doi.org\/10.1007\/s00280-025-04750-3","journal-title":"Cancer Chemother Pharmocol"},{"key":"4813_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31608","author":"IJ Cohen","year":"2025","unstructured":"Cohen IJ (2025) After 75 years of methotrexate, can treatment results be improved with appropriate folinic acid rescue. Pediatr Blood Cancer. https:\/\/doi.org\/10.1002\/pbc.31608","journal-title":"Pediatr Blood Cancer"},{"key":"4813_CR3","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1172\/JCI106181","volume":"48","author":"WM Hryniuk","year":"1969","unstructured":"Hryniuk WM, Bertino JR (1969) Treatment of leukemia with large doses of methotrexate and folic acid clinical -biochemical correlates. J Clin Invest 48:2140\u20132155","journal-title":"J Clin Invest"},{"key":"4813_CR4","first-page":"345","volume":"38","author":"FM Sirotnak","year":"1978","unstructured":"Sirotnak FM, Moccio DM, Dorick DM (1978) Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models. Cancer Res 38:345\u2013353","journal-title":"Cancer Res"},{"key":"4813_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.110467","volume":"146","author":"IJ Cohen","year":"2021","unstructured":"Cohen IJ (2021) Folic acid over rescue of high dose MTX: how problematic citations conserve discredited concepts. Med Hypotheses 146:110467","journal-title":"Med Hypotheses"},{"key":"4813_CR6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1056\/NEJM198602203140803","volume":"314","author":"WE Evans","year":"1986","unstructured":"Evans WE, Crom WR, Abramowitch M et al (1986) Clinical pharmacodynamics of intravenous methotrexate in acute lymphocytic leukemia.Identification of a relationship between concentration and effect. New Eng J Med 314:471\u2013478","journal-title":"New Eng J Med"},{"key":"4813_CR7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/MPH.0b013e31820ee239","volume":"34","author":"WL Salzer","year":"2012","unstructured":"Salzer WL, Winick NJ, Wacker P et al (2012) Plasma methotrexate, red blood cell methotrexate, and red cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia: a report from the children\u2019s oncology group. J Pediatr Hematol Oncol 34:e1\u2013e7. https:\/\/doi.org\/10.1097\/MPH.0b013e31820ee239","journal-title":"J Pediatr Hematol Oncol"},{"key":"4813_CR8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-150870","volume":"112","author":"IJ Cohen","year":"2008","unstructured":"Cohen IJ (2008) High dose compared with intermediate dose methotrexate in children with a first relapse of acute lymphatic leukemia. Blood 112:910","journal-title":"Blood"},{"key":"4813_CR9","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.22.01760","volume":"41","author":"M Campbell","year":"2023","unstructured":"Campbell M, Kiss C, Zimmermann M (2023) Childhood acute lymphoblastic leukemia: results of the randomized acute lymphoblastic leukemia intercontinental -berlin- frankfurt-munster 2009 trial. J Clin Oncol 41:3499\u20133511","journal-title":"J Clin Oncol"},{"key":"4813_CR10","doi-asserted-by":"crossref","unstructured":"Wall AM, Gajjar A, Link A, Pui C-H, Relling MV (2000) Individualized methotrexate dosing for children with relapsed acute lymphoblastic leukemia. Leukemia 14:221\u2013225","DOI":"10.1038\/sj.leu.2401673"},{"key":"4813_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/MPH.0000000000000696","volume":"39","author":"JH Foster","year":"2017","unstructured":"Foster JH, Bernhardt MB, Thompson PA, Smith EO, Schafer ES (2017) Using a bedside algorithm to individually dose high -Dose methotrexate for patients at high risk of toxicity. J Ped Hematol Oncol 39:72\u201376","journal-title":"J Ped Hematol Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04813-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04813-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04813-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T07:34:52Z","timestamp":1759476892000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04813-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4813"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04813-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"8 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}